A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 18, 2016

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions

Congenital Adrenal Hyperplasia

Interventions

DRUG

Hydrocortisone

Modified release hydrocortisone

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

Neurocrine UK Limited

INDUSTRY

NCT03062280 - A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH | Biotech Hunter | Biotech Hunter